ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC
Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.
Related Articles
AACR Annual Meeting
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Proactive ctDNA Monitoring May Guide Earlier Intervention in Endocrine-Resistant HR+/HER2– Breast Cancer
Jason A. Mouabbi, MD, discusses the use of ctDNA to enhance early detection of ESR1 or other resistance mutations in HR-positive breast cancer.
Avutometinib/Defactinib Combo Shows Potential in Recurrent Mesonephric Gynecologic Cancer
Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.
T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy
The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.
Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer
Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.
AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs
Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.
Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC
Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies
Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL
A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.